Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07581340 · ClinicalTrials.gov registry record · NA
Using AI to Improve Sepsis Quality of Care in the Emergency Department
A NA study, sponsored by University of California, San Diego.
- Completed
- Registry status
- NA
- Development phase
- 66
- Enrollment target
NCT07581340: Completed NA study, sponsored by University of California, San Diego.
NCT07581340 is a NA study that has completed, run by University of California, San Diego. The registered enrollment target is 66 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07581340, a NA study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
Study Summary
Sepsis is a life-threatening condition caused by the body's response to infection and is a leading cause of death worldwide. Hospitals use a complex quality measure called SEP-1 to track whether patients with severe sepsis or septic shock receive recommended care, such as timely antibiotics, fluids, and laboratory testing. However, evaluating SEP-1 is difficult. It requires manual review of medical records, is time-consuming and expensive, and typically provides feedback to clinicians months after care is delivered. This delay limits the ability to improve care in real time. This study tested whether artificial intelligence (AI), specifically a type of system called a large language model (LLM), could improve the quality of sepsis care by providing faster and more detailed feedback to physicians. The study was conducted at two emergency departments within a large academic health system. Sixty-six attending physicians were randomly assigned to one of two groups. In the intervention group, the AI system reviewed each patient's medical record at the time of hospital discharge and determined whether SEP-1 care standards were met. Physicians then received near real-time, individualized feedback about their performance, including specific areas for improvement. In the control group, physicians received standard feedback based on a small sample of cases reviewed months later using traditional methods.
Primary Outcome
SEP-1 (the Severe Sepsis and Septic Shock Early Management Bundle) is a quality measure developed by the Centers for Medicare \& Medicaid Services that evaluates whether patients with sepsis receive a set of time-sensitive interventions and diagnostic tests. It is a binary process measure (e.g., either a "pass" or "fail").
Interventions
- BEHAVIORAL Near-real time automated feedback on SEP-1 performance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2024-12-01 |
| Est. Completion | 2025-12-12 |
| Phase | NA |
What the finished NCT07581340 record still lists
NCT07581340 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Near-real time automated feedback on SEP-1 performance is the first listed.
NCT07581340 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07581340 about?
NCT07581340 is a clinical study titled "Using AI to Improve Sepsis Quality of Care in the Emergency Department". Sepsis is a life-threatening condition caused by the body's response to infection and is a leading cause of death worldwide. Hospitals use a complex quality measure called SEP-1 to track whether patients with severe sepsis or septic shock receive recommended care, such as timely antibiotics, fluids,...
What is the current status of trial NCT07581340?
This trial is currently completed. It is a NA study. The enrollment target is 66 participants. The study started on 2024-12-01. Estimated completion is 2025-12-12.
What interventions are being tested in trial NCT07581340?
The interventions under investigation include: Near-real time automated feedback on SEP-1 performance (BEHAVIORAL).
Who is sponsoring clinical trial NCT07581340?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07581340's enrollment target sits among peer trials
66 1139th of 2000 higher than 857 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI